Fluicell

Fluicell Receivables

The Accounts Receivable of Fluicell (FLUI.ST) as of Oct 21, 2026 is 327,000.00 SEK. In the previous year, Accounts Receivable was 216,000.00 SEK — a change of 51.39% (higher).

Receivables

327,000.00SEK

YoY

51.39%

Last updated:

Accounts Receivable of Fluicell is 2024 327,000.00 SEK. Accounts Receivable of Fluicell was 2023 216,000.00 SEK. It decreases by 51.39% higher compared to the previous year.

The Fluicell Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
746,000.00 SEK
Jan 1, 2018
10,000.00 SEK
Jan 1, 2019
735,000.00 SEK
Jan 1, 2020
1.02 M SEK
Jan 1, 2021
575,000.00 SEK
Jan 1, 2022
1.52 M SEK
Jan 1, 2023
216,000.00 SEK
Jan 1, 2024
327,000.00 SEK
The Fluicell Receivables history
YEARReceivablesYoY
327,000.00SEK+51.39%
216,000.00SEK-85.81%
1.52 MSEK+164.70%
575,000.00SEK-43.68%
1.02 MSEK+38.91%
735,000.00SEK+7,250.00%
10,000.00SEK-98.66%
746,000.00SEK-0.27%
748,000.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Accounts Receivable of Fluicell is 327,000.00 SEK in 2024.

Accounts Receivable of Fluicell changed from 216,000.00 SEK to 327,000.00 SEK, representing a 51.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Fluicell since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fluicell

All Key Metrics — Fluicell